JP6389172B2 - 体外式膜型人工肺におけるアンチトロンビンの使用 - Google Patents

体外式膜型人工肺におけるアンチトロンビンの使用 Download PDF

Info

Publication number
JP6389172B2
JP6389172B2 JP2015525617A JP2015525617A JP6389172B2 JP 6389172 B2 JP6389172 B2 JP 6389172B2 JP 2015525617 A JP2015525617 A JP 2015525617A JP 2015525617 A JP2015525617 A JP 2015525617A JP 6389172 B2 JP6389172 B2 JP 6389172B2
Authority
JP
Japan
Prior art keywords
antithrombin
administered
produced
composition according
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015525617A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524823A5 (enExample
JP2015524823A (ja
Inventor
ロウリー，サイモン
フリーリング，ジョアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB USA Inc
Original Assignee
LFB USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB USA Inc filed Critical LFB USA Inc
Publication of JP2015524823A publication Critical patent/JP2015524823A/ja
Publication of JP2015524823A5 publication Critical patent/JP2015524823A5/ja
Application granted granted Critical
Publication of JP6389172B2 publication Critical patent/JP6389172B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2015525617A 2012-08-03 2013-08-02 体外式膜型人工肺におけるアンチトロンビンの使用 Expired - Fee Related JP6389172B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261679345P 2012-08-03 2012-08-03
US61/679,345 2012-08-03
PCT/US2013/053365 WO2014022748A1 (en) 2012-08-03 2013-08-02 The use of antithrombin in extracorporeal membrane oxygenation

Publications (3)

Publication Number Publication Date
JP2015524823A JP2015524823A (ja) 2015-08-27
JP2015524823A5 JP2015524823A5 (enExample) 2016-09-23
JP6389172B2 true JP6389172B2 (ja) 2018-09-12

Family

ID=50028554

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015525617A Expired - Fee Related JP6389172B2 (ja) 2012-08-03 2013-08-02 体外式膜型人工肺におけるアンチトロンビンの使用

Country Status (13)

Country Link
US (1) US9511087B2 (enExample)
EP (1) EP2879697A4 (enExample)
JP (1) JP6389172B2 (enExample)
KR (1) KR20150039201A (enExample)
CN (1) CN104884080A (enExample)
AR (1) AR091977A1 (enExample)
AU (1) AU2013296240B2 (enExample)
BR (1) BR112015002321A2 (enExample)
CA (1) CA2879763C (enExample)
IL (1) IL236776A0 (enExample)
MX (1) MX2015001508A (enExample)
TW (1) TW201425332A (enExample)
WO (1) WO2014022748A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501365A1 (en) 2010-12-30 2013-09-16 Laboratoire Francais Du Fractionnment Et Des Biotechnologies Glycols as pathogen inactivating agents
AR091977A1 (es) 2012-08-03 2015-03-11 Revo Biolog Inc El uso de antitrombina en la oxigenacion de membranas extracorporeas
BR112015019341A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal
EP2956003A2 (en) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Proteins with modified glycosylation and methods of production thereof
JP2016532100A (ja) 2013-07-05 2016-10-13 ラボラトワール・フランセ・デュ・フラクシオンマン・エ・デ・ビョテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ Ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ Ｅｔ Ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ アフィニティークロマトグラフィーマトリックス
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EP3388140A1 (en) * 2017-04-10 2018-10-17 Gambro Lundia AB Extracorporeal blood circuit

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517294A (en) 1982-03-03 1985-05-14 Genentech, Inc. Human antithrombin III
US4632981A (en) 1982-07-30 1986-12-30 Genentech, Inc. Human antithrombin III
US6727405B1 (en) 1986-04-09 2004-04-27 Genzyme Corporation Transgenic animals secreting desired proteins into milk
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
US5322775A (en) 1986-06-30 1994-06-21 Pharmaceutical Proteins Ltd. Peptide production
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5439446A (en) 1994-06-30 1995-08-08 Boston Scientific Corporation Stent and therapeutic delivery system
DE4028800A1 (de) 1990-09-11 1992-03-12 Behringwerke Ag Gentechnische sialylierung von glykoproteinen
DE4326665C2 (de) 1993-08-09 1995-07-13 Biotest Pharma Gmbh Verfahren zur Sterilfiltration von Milch
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5843705A (en) * 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US5801063A (en) 1995-05-09 1998-09-01 Grandics; Peter Device and process for the biospecific removal of heparin
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
EP0973934A4 (en) 1997-02-25 2003-02-05 Genzyme Transgenics Corp TRANSGEN PRODUCED NON-SECRETED PROTEINS.
US20060264357A1 (en) 1997-04-22 2006-11-23 Zikria Bashir A Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals
US8257724B2 (en) 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
DE10159556A1 (de) 2001-12-05 2003-06-12 Aventis Behring Gmbh Intellect Antithrombin III zur Präventation und Therapie vaskuloproliferativer Erkrankungen
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
JP2007503838A (ja) 2003-09-05 2007-03-01 ジーティーシー バイオセラピューティクス， インコーポレイティド トランスジェニック動物の乳汁中での融合タンパク質の産生方法
CA2479968A1 (en) 2004-09-01 2006-03-01 Keith R. Walley Protein c and endothelial protein c receptor polymorphisms as indicators of patient outcome
WO2006007213A1 (en) 2004-06-23 2006-01-19 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
AU2006261555A1 (en) 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor lll polymorphisms associated with prediction of subject outcome and response to therapy
WO2007014244A2 (en) 2005-07-25 2007-02-01 Gtc Biotherapeutics, Inc. Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile
NZ568433A (en) 2005-10-21 2012-07-27 Gtc Biotherapeutics Inc Milk-derived antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
US20070292407A1 (en) 2005-12-12 2007-12-20 The Board Of Trustees Operating Michigan State University Methods of treatment for meconium aspiration syndrome
US7531632B2 (en) 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
WO2007124019A2 (en) 2006-04-21 2007-11-01 Gtc Biotherapeutics, Inc. Methods and products related to the transfer of molecules from blood to the mammary gland
US20100016173A1 (en) 2008-01-30 2010-01-21 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
US20110082083A1 (en) 2009-04-10 2011-04-07 Gtc Biotherapeutics, Inc. Formulations of liquid stable antithrombin
US8551096B2 (en) 2009-05-13 2013-10-08 Boston Scientific Scimed, Inc. Directional delivery of energy and bioactives
BR112014000217A2 (pt) 2011-07-07 2017-02-07 Revo Biologics Inc formulação e método para a criação de uma formulação que estabiliza a proteína terapêutica
TW201400499A (zh) 2012-03-12 2014-01-01 Revo Biolog Inc 抗凝血酶用於治療妊娠毒血症之用途
AR091977A1 (es) 2012-08-03 2015-03-11 Revo Biolog Inc El uso de antitrombina en la oxigenacion de membranas extracorporeas

Also Published As

Publication number Publication date
US20140194360A1 (en) 2014-07-10
CA2879763A1 (en) 2014-02-06
EP2879697A4 (en) 2016-01-20
AU2013296240B2 (en) 2018-05-17
EP2879697A1 (en) 2015-06-10
CA2879763C (en) 2020-12-01
MX2015001508A (es) 2015-04-08
TW201425332A (zh) 2014-07-01
KR20150039201A (ko) 2015-04-09
AU2013296240A1 (en) 2015-02-12
US9511087B2 (en) 2016-12-06
IL236776A0 (en) 2015-03-31
JP2015524823A (ja) 2015-08-27
BR112015002321A2 (pt) 2019-10-22
AR091977A1 (es) 2015-03-11
WO2014022748A1 (en) 2014-02-06
CN104884080A (zh) 2015-09-02

Similar Documents

Publication Publication Date Title
JP6389172B2 (ja) 体外式膜型人工肺におけるアンチトロンビンの使用
US20230000911A1 (en) Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders
US12171740B2 (en) Compositions and methods for treating allergic inflammatory conditions
JP2015509984A (ja) 子癇前症の治療におけるアンチトロンビンの使用
EP1031352B1 (en) Use of desmopressin in the preparation of a metastatic dissemination inhibitor medicament during cancer surgery
CN105431165A (zh) 用于治疗心肺手术后的术后并发症的组合物和方法
TWI823085B (zh) 嗜中性白血球活化調節劑
Davis et al. Use of thromboelastograph and factor VII for the treatment of postoperative bleeding in a pediatric patient on ECMO after cardiac surgery
US10478475B2 (en) Use of von Willebrand factor
EP2476426A1 (en) Treatment and prevention of symptoms of metabolic syndrome
US9546381B2 (en) Use of anticoagulants in the production of recombinant proteins in the milk of transgenic animals
JP2007137771A (ja) 炎症性疾患治療剤、およびその利用
CN114366750A (zh) Xmu-mp-1在制备预防和/或治疗免疫性血小板减少症itp药物中的应用
HK1031820A (en) Use of desmopressin in the preparation of a metastatic dissemination inhibitor medicament during cancer surgery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170921

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180509

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180625

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180717

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180816

R150 Certificate of patent or registration of utility model

Ref document number: 6389172

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees